The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy
Open accessAbstract
Toll-like receptors (TLRs) have first been characterized for their capacity to detect conserved microbial components like lipopolysaccharide (LPS) and double-stranded RNA, resulting in the elicitation of potent (innate) immune responses against invading pathogens. More recently, TLRs have also been shown to promote the activation of the cognate immune system against cancer cells. Today, only three TLR agonists are approved by FDA for use in humans: the bacillus Calmette-Guérin (BCG), monophosphoryl lipid A (MPL) and imiquimod. BCG (an attenuated strain of Mycobacterium bovis) is mainly used as a vaccine against tuberculosis, but also for the immunotherapy of in situ bladder carcinoma. MPL (derived from the LPS of Salmonella minnesota) is included in the formulation of Cervarix®, a vaccine against human papillomavirus-16 and -18. Imiquimod (a synthetic imidazoquinoline) is routinely employed for actinic keratosis, superficial basal cell carcinoma, and external genital warts (condylomata acuminata). In this Trial Watch, we will summarize the results of recently completed clinical trials and discuss the progress of ongoing studies that have evaluated/are evaluating FDA-approved TLR agonists as off-label medications for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3
Alexopoulou, L., Holt, A. C., Medzhitov, R., & Flavell, R. A. (2001) · Nature · doi:10.1038/35099560 · Cited by 6,129
Sterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051
Anderson, K. V., Jürgens, G., & Nüsslein-Volhard, C. (1985) · Cell · doi:10.1016/0092-8674(85)90274-0 · Cited by 691
Zbar, B., Bernstein, I., Tanaka, T., & Rapp, H. J. (1970) · Science · doi:10.1126/science.170.3963.1217 · Cited by 136
Cited by
The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
Galon, J., Angell, H. K., Bedognetti, D., & Marincola, F. M. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.008 · Cited by 864
Self-citationConsensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationFortifying the barrier: the impact of lipid A remodelling on bacterial pathogenesis
Needham, B. D., & Trent, M. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3047 · Cited by 565
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
Self-citationPhototherapy in cancer treatment: strategies and challenges
Cai, Y., Chai, T., Nguyen, W., Liu, J., Xiao, E., Ran, X., Ran, Y., Du, D., Chen, W., & Chen, X. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02140-y · Cited by 453
The Yin and Yang of Toll-like receptors in cancer
Pradere, J.-P., Dapito, D. H., & Schwabe, R. F. (2014) · Oncogene · doi:10.1038/onc.2013.302 · Cited by 331
Trial watch: IDO inhibitors in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A., Sautès-Fridman, C., Tartour, E., Kennedy, E. P., Platten, M., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.957994 · Cited by 326
Self-citationTLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 285
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Makkouk, A., & Weiner, G. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2538 · Cited by 285
Ni, Q., Zhang, F., Liu, Y., Wang, Z., Yu, G., Liang, B., Niu, G., Su, T., Zhu, G., Lu, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaw6071 · Cited by 281
Antitumour dendritic cell vaccination in a priming and boosting approach
Harari, A., Graciotti, M., Bassani-Sternberg, M., & Kandalaft, L. E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0074-8 · Cited by 271
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Senovilla, L., Eggermont, A., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23510 · Cited by 265
Self-citationTrial watch: Oncolytic viruses for cancer therapy
Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24612 · Cited by 255
Self-citationTrial watch: TLR3 agonists in cancer therapy
Le Naour, J., Galluzzi, L., Zitvogel, L., Kroemer, G., & Vacchelli, E. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1771143 · Cited by 239
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124
Type I IFN activating type I dendritic cells for antitumor immunity
Liang, Y., Hannan, R., & Fu, Y.-X. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2564 · Cited by 91
Translational therapies for multiple system atrophy: Bottlenecks and future directions
Stefanova, N. (2018) · Autonomic Neuroscience · doi:10.1016/j.autneu.2017.09.016 · Cited by 12
Metadata
- Authors
- Vacchelli, E., Galluzzi, L., Eggermont, A., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., Zitvogel, L., & Kroemer, G.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2012-09
- Volume
- 1
- Issue
- 6
- Pages
- 894-907
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2059453959
- Cited by
- 244
- References
- 5
- FWCI
- 11.22
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.